Results 11 to 20 of about 57,115 (246)

Full-profile pharmacokinetics, anticancer activity and toxicity of an extended release trivalent PEGylated irinotecan prodrug

Acta Pharmaceutica Sinica B, 2023
Irinotecan is an anticancer topoisomerase I inhibitor that acts as a prodrug of the active metabolite, SN-38. Unfortunately, the limited utility of irinotecan is attributed to its pH-dependent stability, short half-life and dose-limiting toxicity.
Jingkai Gu, John Paul Fawcett
exaly   +3 more sources

Irinotecan Pharmacogenomics [PDF]

Pharmacogenomics, 2010
Irinotecan is a camptothecin analog used as an anticancer drug. Severe, potentially life-threatening toxicities can occur from irinotecan treatment. Although multiple genes may play a role in irinotecan activity, the majority of evidence to date suggests that variation in expression of UGT1A1 caused by a common promoter polymorphism (UGT1A1*28) is ...
Sharon, Marsh, Janelle M, Hoskins
openaire   +4 more sources

Irinotecan-Induced Dysarthria [PDF]

Case Reports in Oncology, 2012
Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease. Here, we describe the case of a 46-year-old patient with metastatic rectal carcinoma who received second-line therapy with irinotecan and developed isolated transient dysarthria (with normal MR imaging of the
Dressel, A.J., van der Mijn, J.C., Aalders, I.J., Rinkel, R.N.P.M., van der Vliet, J.J.   +4 more
openaire   +5 more sources

Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity [PDF]

BMC Microbiology, 2023
Background Irinotecan is a chemotherapeutic agent used to treat a variety of tumors, including colorectal cancer (CRC). In the intestine, it is transformed into SN-38 by gut microbial enzymes, which is responsible for its toxicity during excretion ...
Marwa S. Mahdy, Ahmed F. Azmy, Tarek Dishisha, Wafaa R. Mohamed, Kawkab A. Ahmed, Ahmed Hassan, Sahar El Aidy, Ahmed O. El-Gendy   +7 more
doaj   +3 more sources

Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma

Cancer Medicine, 2023
Background Subgroup analyses of the NAPOLI‐1 study identified that among patients who were irinotecan naïve prior to entering the clinical trial, a survival benefit was observed between the study arm and control arm.
Kenneth H. Yu, Paul Cockrum, Andy Surinach, Neil Lamarre, Shu Wang, Eileen M. O'Reilly   +5 more
doaj   +2 more sources

Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer

BMC Gastroenterology, 2018
Background For patients with advanced gastric cancer (AGC), second-line chemotherapy regimen remains controversial. The efficacy and safety of irinotecan-containing doublet treatment and irinotecan monotherapy were compared in this systematic analysis ...
Liuting Yang, Xiaoyue Jiang, Han Yan, Yingying Li, Hongchao Zhen, Bingmei Chang, Seyed Kariminia, Qin Li   +7 more
doaj   +2 more sources

Protective role of Lactobacillus plantarum A7 against irinotecan-induced genotoxicity [PDF]

Avicenna Journal of Phytomedicine, 2016
Objective: Irinotecan is a botanical derivative and an anti-cancer drug with cytotoxic and genotoxic effects. The present study evaluated the effect of Lactobacillus plantarum A7 on the genotoxic activity of irinotecan in a hepatocellular carcinoma cell ...
Soheila Sepahi, Abbas Jafarian-Dehkordi, Maryam Mirlohi, kobra shirani, Mahmoud Etebari   +4 more
doaj   +1 more source

Economic evaluation of the second-line regimen of liposome irinotecan (II) combined with 5-FU/LV versus placebo combined with 5-FU/LV for locally advanced or metastatic pancreatic ductal adenocarcinoma in China. [PDF]

PLoS ONE
BackgroundThe cost-effectiveness of liposome irinotecan (II) (HR070803) in combination with 5-fluorouracil and leucovorin as a treatment for patients with locally advanced or metastatic pancreatic ductal adenocarcinoma offering a potential new standard ...
Jinlong Huang, Hanyun Ye, Jingyang Lin, Dan Luo, Ping Huang, Xiaochun Zheng   +5 more
doaj   +2 more sources

Quimioterapia con fármacos nuevos en el cáncer de pulmón de célula no pequeña avanzado [PDF]

, 2004
[spa] El cáncer de pulmón es el cáncer más frecuente en todo el mundo. A principio de la década de los 90 aparecieron varios fármacos con una actividad prometedora en cáncer de pulmón de célula no pequeña (CPCNP). El núcleo de esta tesis doctoral son dos
Cardenal Alemany, Felipe
core   +7 more sources

Hepatic ROS Mediated Macrophage Activation Is Responsible for Irinotecan Induced Liver Injury

Cells, 2022
Irinotecan is the first line chemotherapy drug used for treatment of metastatic colorectal cancer worldwide. There is increasing evidence suggesting that liver damage, including steatosis and steatohepatitis, can be caused during the treatment involving ...
Bohao Liu, Cong Ding, Wenbin Tang, Chen Zhang, Yiying Gu, Zhiqiang Wang, Tingzi Yu, Zhuan Li   +7 more
doaj   +1 more source